Breaking News Instant updates and real-time market news.

CDNA

CareDx

$3.55

-0.21 (-5.59%)

13:07
10/03/16
10/03
13:07
10/03/16
13:07

CareDx calls for reversal of reimbursement cut to diagnostic test

CareDx said this morning it is calling for a reversal of a decision by the Centers for Medicare & Medicaid Services to reduce reimbursement for its diagnostic test AlloMap -- the only FDA-cleared blood test to monitor heart transplant patients for rejection, and the only alternative to more costly and invasive biopsies, according to the company. "This decision is unwise, unfair, and misaligned with President Obama's Precision Medicine Initiative," remarked CEO Peter Maag, who called on CMS to reconsider and reverse its proposed 32% decrease in reimbursement -- from $2,821 to $1,920.93. Maag expressed confidence that CMS will reconsider the decision, saying, "The transplant community of providers, patients, and caregivers will continue to engage with CMS during the reconsideration process." If left unchanged, the new rate would take effect as of January 1, 2017. "This process is only being used due to the delay in implementation of PAMA, where this type of reduction in reimbursement would not be permitted... AlloMap is used in the vast majority of heart transplant centers nationwide, with more than 75,000 commercial tests performed to date. During this time CareDx has never increased the price of AlloMap. CareDx has continued to further invest in improvements of the technology and new transplant services despite not having made a profit on AlloMap," the company added.

  • 15

    Nov

CDNA CareDx
$3.55

-0.21 (-5.59%)

06/13/16
LEER
06/13/16
NO CHANGE
LEER
CMS price proposals for diagnostic tests a negative for most, says Leerink
Leerink analyst Dan Leonard expects several diagnostics stocks to underperform following proposed price cuts or low initial reimbursement rates by the Centers for Medicare and Medicaid Services, or CMS, for diagnostic tests. If finalized, the preliminary pricing would negatively impact CareDx (CDNA), Veracyte (VCYT), and InVitae (NVTA), the analyst tells investors in a research note, adding that he also sees an indirect negative read-through for Illumina (ILMN).
06/13/16
CANT
06/13/16
NO CHANGE
Target $13
CANT
Buy
Cantor sees 'flawed methodology' with new CMS rates
Cantor Fitzgerald analyst Bryan Brokmeier says shares of Veracyte (VCYT) may be under pressure this morning following Friday's release of a proposed gapfill Medicare reimbursement rate reduction on the company's Afirma GEC. Along with the 30% reduction on Afirma's GEC, the release from the Centers for Medicare and Medicaid Services resets rates on 15 other molecular diagnostic tests, including reductions in CareDx's (CNDA) AlloMap, which is down 74%, Genomic Health's (GHDX) Oncotype Dx Colon, which is down 73%, and Rosetta Genomics' (ROSG) Cancer Origin Test, which is down 57%, Brokmeier tells investors in a research note. The analyst, however, believes the preliminary proposed gapfill rate is based on a "flawed methodology" because it is the median proposed rate submitted by all Medicare Administrative Contractors, including those that have little or no experience administering claims on these tests, Brokmeier contends. He points out that Medicare represents approximately 20% of Afirma GEC test volume for Veracyte. Based on 2015 volume, the 30% Medicare rate reduction for Afirma would reduce total revenues by $3.7M or 7.5%, he adds. The analyst keeps a Buy rating on Veracyte with a $13 price target.
06/20/16
PIPR
06/20/16
NO CHANGE
PIPR
Final PAMA rule better than expected, says Piper Jaffray
Piper Jaffray analyst William Quirk says the final Protecting Access to Medicare Act published Friday by Centers for Medicare & Medicaid Services is better than expected. PAMA is delayed until 2018 from 2017 as expected, Quirk tells investors in a research note. Hospital labs will be required to submit private payer rates to CMS, a positive relative to prior expectations, the analyst notes. He views the decision as beneficial for Quest Diagnostics (DGX) and LabCorp (LH). Further, CMS will require labs to submit only in-network rates and out-of-network "final" rates, which is a positive for specialty labs who have in-network rates at or above Medicare including CareDx (CDNA), Genomic Health (GHDX), Myriad Genetics (MYGN), Oxford Immunotec (OXFD) and Veracyte (VCYT), Quirk writes.
07/07/16
PIPR
07/07/16
NO CHANGE
PIPR
New FDA recommendation positive for lab companies, says Piper Jaffray
Piper Jaffray analyst William Quirk says that the FDA has issued draft guidance to streamline its approval process for next-generation sequencing, or NGS, germline tests, which could be a substitute for a Premarket Notification or 510k. The analyst believes streamlined regulatory approaches for NGS tests are a positive for labs with NGS laboratory-developed tests such as CareDx (CDNA), Quest Diagnostics (DGX), Genomic Health (GHDX), LabCorp (LH), Myriad Genetics (MYGN), Natera (NTRA), Oxford Immunotec (OXFD), Sequenom (SQNM), Trovagene (TROV), and Veracyte (VCYT).

TODAY'S FREE FLY STORIES

CSGP

CoStar Group

$210.02

-1.35 (-0.64%)

17:24
02/22/17
02/22
17:24
02/22/17
17:24
Earnings
Breaking Earnings news story on CoStar Group »

CoStar Group sees Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 27

    Feb

  • 16

    Mar

  • 21

    Mar

  • 22

    Mar

  • 22

    Mar

  • 23

    Mar

  • 27

    Mar

  • 28

    Mar

CSGP

CoStar Group

$210.02

-1.35 (-0.64%)

17:24
02/22/17
02/22
17:24
02/22/17
17:24
Hot Stocks
Breaking Hot Stocks news story on CoStar Group »

CoStar Group sees FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 27

    Feb

  • 16

    Mar

  • 21

    Mar

  • 22

    Mar

  • 22

    Mar

  • 23

    Mar

  • 27

    Mar

  • 28

    Mar

CSGP

CoStar Group

$210.02

-1.35 (-0.64%)

17:22
02/22/17
02/22
17:22
02/22/17
17:22
Earnings
Breaking Earnings news story on CoStar Group »

CoStar Group sees Q1 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 27

    Feb

  • 16

    Mar

  • 21

    Mar

  • 22

    Mar

  • 22

    Mar

  • 23

    Mar

  • 27

    Mar

  • 28

    Mar

IAG

IAMGold

$4.41

-0.05 (-1.12%)

17:20
02/22/17
02/22
17:20
02/22/17
17:20
Hot Stocks
Breaking Hot Stocks news story on IAMGold »

IAMGold sees 2017 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IAG

IAMGold

$4.41

-0.05 (-1.12%)

17:19
02/22/17
02/22
17:19
02/22/17
17:19
Hot Stocks
Breaking Hot Stocks news story on IAMGold »

IAMGold sees 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IAG

IAMGold

$4.41

-0.05 (-1.12%)

17:17
02/22/17
02/22
17:17
02/22/17
17:17
Earnings
IAMGold reports Q4 EPS 0c, consensus 0c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GGG

Graco

$91.94

-0.18 (-0.20%)

17:17
02/22/17
02/22
17:17
02/22/17
17:17
Hot Stocks
Graco rebrands, redesigns Airlessco airless sprayer line »

Graco launched a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

DDC

Dominion Diamond

$9.21

-0.27 (-2.85%)

17:16
02/22/17
02/22
17:16
02/22/17
17:16
Hot Stocks
Dominion Diamond sees FY18 production 6.3M-7M carats »

During fiscal 2018, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OAS

Oasis Petroleum

$13.66

-0.68 (-4.74%)

17:15
02/22/17
02/22
17:15
02/22/17
17:15
Hot Stocks
Oasis Petroleum projects FY17 CapEx $605M »

Sees Fy17 production…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 05

    Mar

OAS

Oasis Petroleum

$13.66

-0.68 (-4.74%)

17:14
02/22/17
02/22
17:14
02/22/17
17:14
Hot Stocks
Oasis Petroleum reports Q4 non-GAAP EPS (8c), consensus (12c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 05

    Mar

DDC

Dominion Diamond

$9.21

-0.27 (-2.85%)

17:13
02/22/17
02/22
17:13
02/22/17
17:13
Hot Stocks
Dominion Diamond reports Q4 diamond sales $129.9M »

During the fourth fiscal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$16.20

0.07 (0.43%)

17:13
02/22/17
02/22
17:13
02/22/17
17:13
Earnings
HP Inc. sees FY17 adjusted EPS $1.55-$1.65, consensus $1.59 »

Sees FY17 free cash flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 17

    Apr

CAKE

Cheesecake Factory

$60.10

-0.57 (-0.94%)

17:12
02/22/17
02/22
17:12
02/22/17
17:12
Earnings
Cheesecake Factory sees FY17 adjusted EPS $2.95-$3.07, consensus $3.05 »

Backs FY17 SSS growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 08

    Mar

CAKE

Cheesecake Factory

$60.10

-0.57 (-0.94%)

17:11
02/22/17
02/22
17:11
02/22/17
17:11
Earnings
Cheesecake Factory sees Q1 adjusted EPS 71c-74c, consensus 73c »

Sees Q1 SSS growth flat…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 08

    Mar

IOC

InterOil

$48.36

-0.04 (-0.08%)

, XOM

Exxon Mobil

$80.93

-0.96 (-1.17%)

17:11
02/22/17
02/22
17:11
02/22/17
17:11
Hot Stocks
Exxon Mobil completes acquisition of InterOil »

InterOil (IOC) completed…

IOC

InterOil

$48.36

-0.04 (-0.08%)

XOM

Exxon Mobil

$80.93

-0.96 (-1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RGR

Sturm, Ruger

$50.30

1 (2.03%)

17:09
02/22/17
02/22
17:09
02/22/17
17:09
Hot Stocks
Breaking Hot Stocks news story on Sturm, Ruger »

Sturm Ruger declares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

RGR

Sturm, Ruger

$50.30

1 (2.03%)

17:08
02/22/17
02/22
17:08
02/22/17
17:08
Earnings
Sturm Ruger reports Q4 EPS $1.10 vs. 88c last year »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

ALB

Albemarle

$92.44

-1.34 (-1.43%)

17:07
02/22/17
02/22
17:07
02/22/17
17:07
Hot Stocks
Albemarle and Tianqi terminate option for interest acquisition »

Albemarle and Tianqi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 16

    Mar

LTC

LTC Properties

$47.13

0.24 (0.51%)

17:07
02/22/17
02/22
17:07
02/22/17
17:07
Earnings
LTC Properties reports Q4 FFO 78c vs. 74c last year »

Reports Q4 diluted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 01

    Mar

ERN

Erin Energy

$3.55

-0.1 (-2.74%)

17:05
02/22/17
02/22
17:05
02/22/17
17:05
Hot Stocks
Erin Energy CEO Segun Omidele resigns »

Erin Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRP

Ctrip.com

$47.59

0.53 (1.13%)

17:04
02/22/17
02/22
17:04
02/22/17
17:04
Earnings
Ctrip.com reports Q4 non-GAAP EPS 32c, may not compare to consensus (3c) »

Reports Q4 revenue $730M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

OSIS

OSI Systems

$77.18

-0.51 (-0.66%)

17:04
02/22/17
02/22
17:04
02/22/17
17:04
Hot Stocks
OSI Systems sells German Healthcare unit for roughly EUR11.7M »

OSI Systems announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLX

TPG Specialty Lending

$19.41

-0.02 (-0.10%)

17:03
02/22/17
02/22
17:03
02/22/17
17:03
Hot Stocks
TPG Specialty Lending extends stock repurchase plan »

TPG Specialty Lending…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

RMAX

RE/MAX Holdings

$60.45

0.05 (0.08%)

17:02
02/22/17
02/22
17:02
02/22/17
17:02
Hot Stocks
RE/MAX Holdings raises quarterly dividend 20% to 18c per share »

The quarterly dividend is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 09

    Mar

TSLX

TPG Specialty Lending

$19.41

-0.02 (-0.10%)

17:02
02/22/17
02/22
17:02
02/22/17
17:02
Earnings
TPG Specialty Lending reports Q4 NII 47c, consensus 44c »

Reports net asset value…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.